Phosphoramidic Acid

Phosphoramidic Acid

SCHEMBL113023

COC(=O)CN(CC(=O)OC)C(O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C[C@@H]1O.NP(=O)(O)O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
ENPP1 P22413 3/20 0.49
P2RY1 P47900 2/20 0.49
ADORA3 P0DMS8 3/20 0.45
ADORA1 P30542 2/20 0.45
DNPH1 O43598 1/20 0.45
PRKAB2 O43741 1/20 0.45
TRPM2 O94759 1/20 0.45
LDHA P00338 1/20 0.45
ADRB2 P07550 1/20 0.45
FBP1 P09467 1/20 0.45
SRC P12931 1/20 0.45
P2RY2 P41231 1/20 0.45
PRKAG1 P54619 1/20 0.45
PRKAA2 P54646 1/20 0.45
PDE4D Q08499 1/20 0.45
KCNH2 Q12809 1/20 0.45
PRKAA1 Q13131 1/20 0.45
PDE3A Q14432 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoramidic Acid SCHEMBL110377 0.91 POLB (0.51) POLBENPP1P2RY1ADORA1DNPH1
Phosphoramidic Acid SCHEMBL109783 0.87 POLB (0.50) POLBENPP1P2RY1ADORA1DNPH1
Phosphoramidic Acid SCHEMBL2690062 0.84 POLB (0.49) POLBENPP1P2RY1ADORA1DNPH1
SCHEMBL28000715 0.79 POLB (0.57) POLBENPP1P2RY1ADORA1DNPH1
SCHEMBL8836307 0.78 POLB (0.56) POLBENPP1P2RY1ADORA1DNPH1
SCHEMBL8836270 0.78 POLB (0.56) POLBENPP1P2RY1ADORA1DNPH1
SCHEMBL66046 0.77 AHCY (0.57) POLBENPP1P2RY1AHCY
SCHEMBL5621204 0.76 AHCY (0.52) POLBENPP1P2RY1ADORA3AHCY
SCHEMBL5621212 0.76 AHCY (0.52) POLBENPP1P2RY1ADORA3AHCY
SCHEMBL18952729 0.76 AHCY (0.52) POLBENPP1P2RY1AHCY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108533-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2012-05-03 US disclosed
EP-2424874-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-03-07 EP disclosed
WO-2010125200-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108533-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS PNP, TYMP, MTAP POLB 6/4885ENPP1 46/4885P2RY1 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.